These drugs include treatments for rare diseases, hepatitis C and cancer, such as Merck's own Keytruda ... profile example concerned the new high cholesterol treatments, Sanofi's Praluent and ...

In one study, the drug reduced blood levels of free ... that in trials wasn't able to match the LDL cholesterol-lowering effect of Merck's candidate. Amgen's Repatha (evolocumab) and Sanofi ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

It is nondialysable, and studies in patients with moderate chronic kidney disease (GFR <50 ml/min/1.73 m 2) demonstrated a reduced rate of fenofibrate excretion and accumulation of the drug with ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...